Board summary
Key figures
25,738
Registered population
56.8% aged 18–64
22.1%
Aged 65+
ICB 19.9% · England 17.9%
6.6%
Ethnic minority (non-White)
2.4% Asian · England 9.6%
0.4%
In IMD quintile 1
ICB 17.1% · England 21.0%
~100
Core20 residents (est.)
Resident basis; registered basis ~108 · see page 3
4,325
Hypertension register
+8.43% in 3 yrs · England +5.60%
181
SMI register
10.7% of Maidstone's
466
COPD register
Reviews -41.97% in 3 yrs
Forecast to 2030
5,526
Hypertension patients, 2030
+1,201 on today
54.6%
QRISK ≥20% on statins, 2030
-0.12pp over 3 yrs
7.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual review coverage trails benchmarks.
Asthma review coverage is 45.3% (Maidstone 63.2%, ICB 60.4%, England 65.7%), after a -25.1% three-year change, leaving about 880 patients without a recorded review.
Childhood MMR uptake below 95% target.
In Q1 2025/26, 24-month MMR dose 1 coverage is 82.5% (12.5 pp below the 95% target), with an 8.6 pp age-five first-to-second-dose gap.
Breast and cervical screening exceed England.
Breast screening coverage (ages 53 to 70) is 75.4% (England 69.9%) and cervical screening (ages 25-49) is 73.0% (England 66.8%), outperforming Maidstone and ICB.
Population, age and ethnicity
Athena PCN serves an older population, with 22.1% aged 65 and over
Athena PCN serves 25,738 registered patients through Greensand Medical Group. Patients aged 65 and over make up 22.1% (5,694 people), exceeding Maidstone (18.7%), NHS Kent and Medway ICB (19.9%) and England (17.9%), alongside unverified projected list growth of 7.6% to 2030 (England 2.3%). Patients aged 0-17 comprise 21.1% and aged 18-64 represent 56.8%. Based on Census usual-resident estimates in associated areas rather than practice registrations, 93.4% identify as White (Maidstone 89.8%, ICB 88.6%, England 81.1%), with a 6.6% non-White share and 0.8% identifying as Gypsy or Irish Traveller (Maidstone 0.6%, ICB 0.3%, England 0.1%).
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Maidstone local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Maidstone LA) | 2,653 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 73.8% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 51.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Maidstone LA) | 1,380 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Maidstone LA) | 15.8 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Athena PCN records an average IMD decile of 5.7 and 0.4% Core20 share
Athena PCN records an average IMD decile of 5.7 (Maidstone 5.9, ICB 5.4, England 5.5). Its Core20 share is 0.4% (Maidstone 9.9%, ICB 17.1%, England 21.0%), with 0 associated decile 1 or 2 LSOAs. Resident Core20 count is estimated at about 100, while Greensand Medical Group's registered share yields 108 patients. Low area deprivation may mask pocket need, consistent with register growth in depression (+27.6% vs England +7.7%) and learning disability (+30.4% vs England +5.4%), which clinical audit would test.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
181
SMI register
0.70% recorded prevalence
195
Learning disability register
0.76% recorded prevalence
7
Care homes, 219 beds
In the PCN catchment
8.7%
Provide unpaid care
Maidstone, Census 2021
The PCN records 195 patients with learning disabilities (0.8% prevalence, above Maidstone at 0.6%, ICB at 0.6%, and England at 0.6%) and 181 on the severe mental illness register (0.7%, below Maidstone at 0.9%, ICB at 0.9%, and England at 1.0%). Catchment infrastructure includes 7 care homes with 219 beds. Lower recorded SMI prevalence than England (0.7% vs 1.0%) does not establish under-detection; clinical register audit would test diagnostic capture.
Severe mental illness: physical health checks
Recorded SMI prevalence is 0.7% (England 1.0%). Annual BMI recording fell 3.2 pp over 2023 to 2025 (England +5.1 pp) to 72.3% (England 82.1%), whereas blood pressure checks reached 81.3% (England 83.4%). Metabolic monitoring requires targeted recall.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,325
Hypertension register
+8.43%
Register growth, 3 yrs
Maidstone +4.31% · England +5.60%
−5.16pp
BP control, under 80
≤140/90 · −9.83pp aged 80+
+1,201
More patients by 2030
Forecast 5,526 (19.81%)
Hypertension case-finding and control
Hypertension prevalence is 16.8% (4,325 patients), above Maidstone (16.0%), the ICB (16.2%) and England (15.2%). While 89.5% have a recent blood pressure check (England 90.0%), blood pressure control is 60.7% in under-80s (England 67.8%, falling 7.8% over 2023 to 2025 versus England +3.2%) and 69.1% in those aged 80+ (England 81.2%, falling 12.5% versus England +2.2%). Blood pressure control lags comparators most markedly in older cohorts, indicating an operational priority to intensify clinical review and medication titration.
Lipids and statins
Among patients with QRISK ≥ 20%, 54.9% receive lipid-lowering therapy (England 63.6%, Maidstone 60.3%), down 0.2% over 2023 to 2025 (England +6.2%). In chronic kidney disease, lipid therapy is 65.4% (England 70.3%, ICB 69.2%). Fewer at-risk patients receive lipid-lowering therapy than England benchmarks, indicating an area for proactive recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 37,913 | £1.70 | £1.90 | £1.86 | £64,452 |
| Cardiovascular (all), 2025 | 50,536 | £2.98 | £3.57 | £3.33 | £150,597 |
In 2026, 37,913 lipid-regulating items were prescribed at £1.70 per item (£64,452 annual spend), compared to £1.86 in England and £1.62 in Maidstone. Across these items, the PCN spent £6,066 less than at England's unit cost. Unit cost is a cost indicator rather than an efficiency measure, without establishing case-mix or treatment coverage.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−25.07%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.13%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.7% (1,608 patients), but 12-month reviews fell 25.1% over 2023 to 2025 (England +4.4%) to 45.3% (England 65.7%, Maidstone 63.2%, ICB 60.4%), leaving about 880 patients without a recorded review. COPD prevalence is 1.8% (466 patients), with annual reviews falling 42.0% over 2023 to 2025 (England +2.8%) to 47.4% (England 76.4%, Maidstone 70.6%, ICB 72.5%). Sharp falls could reflect review capacity bottlenecks, unverified locally, which clinical audit would test.
Cancer register and children's immunisation
Recorded cancer prevalence is 5.4% (1,379 patients; England 3.8%). In Q1 2025/26, 24-month MMR1 coverage is 82.5% (England 88.3%, ICB 89.4%). At age 5, MMR1 reaches 93.8% (England 91.7%) while MMR2 is 85.2% (an 8.6 pp gap), and 4-in-1 booster coverage is 84.0%. Lower second-dose and booster completion may reflect recall attrition, unverified locally, which audit would test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of staged cancers in NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (4,661 of 8,384 staged cases; England 55.3%), up 2.2 pp since 2013 but 19.4 pp below the 75.0% national ambition by 2028. Known-stage completeness was 63.6% (8,384 of 13,189 registrations; England 67.0%), requiring about 1,630 extra early-stage diagnoses annually across the ICB. System figures reflect wider pathways rather than PCN performance; locally, ATHENA PCN cancer prevalence is 5.4% (1,379 patients; 3-year change +16.1% vs England +9.0%), with breast screening at 75.4% (England 69.9%) and cervical screening at 73.0% (England 66.8%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Maidstone and Tunbridge Wells NHS Trust achieved 87.4% on 62-day referral to treatment (standard 85.0%; ICB 75.9%, England 71.2%), 81.8% on the 28-day faster diagnosis standard (standard 75.0%; ICB 76.8%, England 79.3%), and 98.3% on 31-day combined treatment (standard 96.0%; ICB 95.8%, England 92.5%). In diagnostics, 6.4% of patients waited 6+ weeks across all tests (England 23.1%), with colonoscopy at 19.8% (England 30.8%) and flexi sigmoidoscopy at 28.2% (England 32.1%). Provider and trust measures describe secondary care activity rather than PCN performance.
| Pathways within standard (%) | Maidstone and Tunbridge Wells | Medway | Dartford and Gravesham | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.78 | 77.77 | 78.14 | 76.78 | 79.32 |
| 31-day treatment (96%) | 98.35 | 99.62 | 97.48 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 87.43 | 81.64 | 63.59 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Maidstone and Tunbridge Wells | Medway | Dartford and Gravesham | England |
|---|---|---|---|---|
| MRI | 0.92 | 0.68 | 0.36 | 21.40 |
| CT | 0.51 | 0.00 | 2.08 | 9.92 |
| Echocardiography | 2.57 | 36.62 | 3.90 | 28.48 |
| Colonoscopy | 19.80 | 1.88 | 0.40 | 30.83 |
| Gastroscopy | 24.03 | 3.32 | 0.00 | 29.02 |
| All 15 DM01 tests | 6.42 | 14.20 | 8.37 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026 (provisional), Kent residents had 210,170 community care contacts across 60,605 patients, with 138,250 contacts (65.8%) among adults aged 65+ and 31,385 among children aged 0-18. Across NHS Kent and Medway Integrated Care Board, 72,060 patients recorded 254,055 contacts (165,655 aged 65+). These provisional experimental figures describe county and ICB activity rather than PCN-specific caseloads.
Practice variation and patient experience
Greensand Medical Group recorded 46.9% good patient experience alongside 100.0% clinical QOF achievement
In 2025/26, Greensand Medical Group attained 100.0% in QOF clinical achievement (England 97.1%) and 90.8% overall (England 92.5%). However, vaccination and immunisation achievement reached 18.9% (England 55.2%), while personalised care adjustments across all domains were 12.4% (England 10.0%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Greensand Medical | 177 | 0.4 | 20.9% | 59.7% | 46.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eighteen of 25 measures trail England over three years, led by clinical reviews
Over 2023 to 2025, 18 of 25 compared measures trailed England. The widest relative declines occurred in annual reviews: heart failure reviews fell 81.1% (England +8.7%), COPD reviews fell 42.0% (England +2.8%), and asthma reviews fell 25.1% (England +4.4%). Conversely, relative strengths included diabetes statin prescribing, which rose 5.2% (England +2.1%), cervical screening at +0.02% (England -1.0%), and rapid register expansions for learning disability (+30.4% vs England +5.4%) and depression (+27.6% vs England +7.7%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Asthma reviews
Diabetes HbA1c control
BP control, 80+
Diabetes statin (no CVD)
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Maidstone | Asset | PCN | Maidstone |
|---|---|---|---|---|---|
| Care homes (catchment) | 7 (219 beds) | n/a | Schools (catchment) | 36 | n/a |
| Children's centres | 1 | 7 | Places of worship | 29 | 94 |
| Libraries | 2 | 9 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | 1 | 3 |
| Children and young people (VCS) | n/a | 3 | Carers support groups (VCS) | 1 | 4 |
| Primary schools (LA maintained) | 8 | 28 | Primary academies | 6 | 14 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma 12-month review completion is 45.3% of the 1,608 register (Maidstone 63.2%, ICB 60.4%, England 65.7%), leaving about 880 patients without a recorded review. For discussion, Greensand Medical Group could run a single-template asthma recall alongside repeat inhaler prescribing checks and flexible review slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension and high-risk lipid recall
On the 4,325 hypertension register, BP control is 69.1% in ages 80+ (England 81.2%) and 60.7% in under-80s (England 67.8%); QRISK >= 20% lipid therapy is 54.9% (England 63.6%). For discussion, the PCN could establish pharmacist-led recall and home BP monitoring titration for uncontrolled hypertension and untreated high-QRISK patients. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Childhood MMR and booster recall
In Q1 2025/26, 24-month MMR1 is 82.5% (12.5 pp below the 95.0% target; England 88.3%), age-5 4-in-1 is 84.0%, and age-5 MMR2 (85.2%) trails MMR1 (93.8%) by 8.6 pp. For discussion, Greensand Medical Group could audit children missing 24-month MMR1 and age-5 boosters and offer catch-up clinic slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Inclusion health outreach (p2) | Gypsy or Irish Traveller | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood booster recall audit (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Suspected cancer pathway safety netting (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Telephony and appointment access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension and high-risk lipid recall (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Childhood MMR and booster recall (p12) | MMR dose 1 coverage at 24 months · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
